A 22-year-old male experiencing hair loss suspects androgenetic alopecia (AGA) and possibly telogen effluvium (TE), with a noted improvement in scalp itch after adopting a gluten-free diet. He is advised to consider treatments like finasteride or minoxidil and to check iron and ferritin levels.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
Dutasteride may not be effective for everyone due to underlying issues, suggesting scalp biopsies for further diagnosis. Users discuss using higher doses of dutasteride, topical treatments, minoxidil, and pyrilutamide for hair loss management.
A 21-year-old shared impressive hair regrowth results after nearly three years using 1mg finasteride and 2.5mg oral minoxidil daily. The user experienced shedding periods but reported no side effects, and the transformation was praised by many.
An 18-year-old has been using 5% topical minoxidil for 2 months for hair loss, with a history of vitamin D deficiency and thyroid imbalance. Users suggest starting finasteride and blocking DHT for androgenetic alopecia (AGA).
A user who experienced significant hair regrowth over the course of one year by following a regimen including finasteride, minoxidil, Nizoral shampoo, dermarolling, biotin vitamins, vitamin D3 and collagen peptides. The post includes before/after photos and details on the brands used.
The user shared their 11-month hair loss treatment experience using Dutasteride daily and Minoxidil initially, noting improvements in hair density and texture. They stopped Minoxidil in February, observed no significant shedding, and plan to continue with Dutasteride, considering reintroducing Minoxidil for more regrowth.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.
As it was at 1 year
This conversation is about a user who has been using finasteride and minoxidil for 18 months to treat hair loss, with positive results. They have also made lifestyle changes such as the use of Hims shampoo and conditioner, gym workouts, and eating proteins on weekdays.
The user has been using finasteride for 11 months, minoxidil for 3 months, and Serioxyl Advanced Denser Hair and alfatradiol pantostin for 1 month to address hair loss. Another user suggests switching from finasteride to dutasteride, but others argue finasteride is effective for the user.
People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.
A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.
Hair transplants, oral finasteride, oral minoxidil, and dutasteride mesotherapy are highly effective for treating AGA hair loss. This combination can maintain and improve hair for most people, except those with very aggressive AGA.
The conversation is about finding a legitimate online source for 17α-estradiol (Alfatradiol) powder to make a 0.1% solution for hair loss treatment. A user suggests Anagenica as a source.
A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.
The conversation is about finding 1.5mm cartridges for a Dr. Pen device, with a preference for purchasing through Amazon. The discussion does not mention specific hair loss treatments like Minoxidil, finasteride, or RU58841.
FalseHour6541's two-year experience with Minoxidil and Finasteride, resulting in good density on their crown; other users suggested a hair transplant to help reduce the receding hairline.
A 27-year-old man shared his 3-month progress using finasteride and minoxidil for hair loss, showing significant improvement and increased confidence. He expressed gratitude to the community for their support and inspiration.
A woman with alopecia universalis shares her positive experience of being bald, finding it freeing and less worrisome. She also discusses her skincare routine using Korean products.
A user is seeking experiences with adenosine for hair loss, asking about its effectiveness, usage duration, and combination with treatments like minoxidil, finasteride, or RU58841. Another user mentions difficulty sourcing adenosine and comments on the mixed quality of research.
A 19-year-old has been using dutasteride, minoxidil tablets, microneedling, and ketoconazole shampoo for hair loss for 120 days and is unsure about the results. Other users see positive progress and encourage consistency, while one asks about side effects.
Breezula is a potential hair loss treatment, but recent updates suggest it may not be as promising as initially thought. Some users express skepticism about its effectiveness based on past results.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.